ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

NCI-Approved Clinical Trials

August 31, 2001

Fisher, Bonadonna, Croce, Hanafusa Win GAM Cancer Prizes

June 11, 1993

Blue Cross, Broder Skirmish On Coverage Of Group C Drugs

November 3, 1989

IG Report Clears Shubik Of Conflict Of Interest Change

October 6, 1978

Risks Of Long-Term HRT Outweigh Benefits, WHI Finds

March 28, 2008

Experts Claim Errors in Breast Cancer Study, Demand Retraction of Practice-Changing Paper

May 18, 2012